在抗高血压药物药物治疗中的新方法
Sidar Copur1, Alexandru Burlacu2,3, Mehmet Kanbay4
1Department of Internal Medicine, Division of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
Current opinion in nephrology and hypertension
|April 23, 2025
概括
新的药物疗法正在出现,以解决非最佳的高血压管理问题,特别是在耐药病例中. 这些新疗法针对各种途径,有望改善患者心血管健康的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 尽管有众多可用的药物,但高血压的管理往往是不理想的.
- 抗性高血压影响大约10%的患者,导致显著的发病率和死亡率.
研究的目的:
- 评估用于管理高血压的新型治疗方法.
- 探索新兴的药物疗法,以改善血压控制.
主要方法:
- 对高血压的近期药物治疗策略的审查.
- 对针对不同病理生理机制的新药剂的分析.
主要成果:
- 几种新型药物正在研究中,包括阿尔多合成酶抑制剂,基于RNA的疗法 (反感性寡核酸,小干扰RNA),心房 natriuretic 类型,双内衣林对抗剂,肠道-交换器-3 抑制剂,化合物17b 和非类固醇矿物质皮质体受体对抗剂.
- 这些新的方法针对与高血压相关的各种病理生理路径.
结论:
- 高血压药物治疗领域正在迅速发展,有望出现新的药物.
- 这些新的治疗方法有可能显著改善高血压患者的临床结果.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Antihypertensive Drugs: Direct Renin Inhibitors
440
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
440
Adrenergic Antagonists: ɑ and β-Receptor Blockers
379
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
379
Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426
Antihypertensive Drugs: Action of Diuretics
572
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
572
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385


